Patents Assigned to Enveric Biosciences Canada Inc.
  • C-carbonothioate-substituted tryptamine derivatives and methods of using
    Patent number: 11945778
    Abstract: Disclosed are novel C4-carbonothioate-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
    Type: Grant
    Filed: May 31, 2023
    Date of Patent: April 2, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Kaveh Matinkhoo, Peter J. Facchini
  • Nitrilated psilocybin derivatives and methods of using
    Patent number: 11931338
    Abstract: Disclosed are novel nitrilated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a nitrile-group containing compound.
    Type: Grant
    Filed: September 16, 2022
    Date of Patent: March 19, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • Multi-substituent psilocybin derivatives and methods of using
    Patent number: 11918594
    Abstract: Disclosed are novel multi-substituent psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a substituent containing compound.
    Type: Grant
    Filed: September 29, 2022
    Date of Patent: March 5, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • Prenylated psilocybin derivatives and methods of using
    Patent number: 11891359
    Abstract: Disclosed are novel prenylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced in vitro or in vivo using a biosynthetic system which comprises cells comprising a prenyl transferase, and, optionally, additional enzymes, including a decarboxylase, and an N-acetyl transferase.
    Type: Grant
    Filed: September 29, 2022
    Date of Patent: February 6, 2024
    Assignee: ENVERIC BIOSCIENCES CANADA INC.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Xue Chen
  • Glycosylated psilocybin derivatives and methods of using
    Patent number: 11891360
    Abstract: Disclosed are novel glycosylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a hydroxylated psilocybin derivative with a glycosyl compound.
    Type: Grant
    Filed: September 9, 2022
    Date of Patent: February 6, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • Aminated psilocybin derivatives and methods of using
    Patent number: 11858895
    Abstract: Disclosed are novel aminated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The aminated psilocybin derivative compounds may be chemically synthesized.
    Type: Grant
    Filed: September 16, 2022
    Date of Patent: January 2, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • C-carbonothioate-substituted tryptamine derivatives and methods of using
    Patent number: 11845726
    Abstract: Disclosed are novel C4-carbonothioate-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: December 19, 2023
    Assignee: ENVERIC BIOSCIENCES CANADA INC.
    Inventors: Jillian M. Hagel, Kaveh Matinkhoo, Peter J. Facchini
  • Aldehyde and ketone derivatives of psilocybin and methods of using
    Patent number: 11845727
    Abstract: Disclosed are novel aldehyde and ketone psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with an aldehyde or ketone group containing compound.
    Type: Grant
    Filed: September 23, 2022
    Date of Patent: December 19, 2023
    Assignee: ENVERIC BIOSCIENCES CANADA INC.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • Carboxylated psilocybin derivatives and methods of using
    Patent number: 11752130
    Abstract: Disclosed are novel carboxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a carboxyl or Carboxylic acid derivative containing compound.
    Type: Grant
    Filed: September 23, 2022
    Date of Patent: September 12, 2023
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
  • C4-carboxylic acid-substituted tryptamine derivatives and methods of using
    Patent number: 11746087
    Abstract: Disclosed are novel C4-carboxylic acid-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: September 5, 2023
    Assignee: ENVERIC BIOSCIENCES CANADA INC.
    Inventors: Jillian M. Hagel, Ye Cai, Kaveh Matinkhoo, David James Press, Glynnis Elizabeth Jensen, Peter J. Facchini
  • C4-carbonothioate-substituted tryptamine derivatives and methods of using
    Patent number: 11707447
    Abstract: Disclosed are novel C4-carbonothioate-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: July 25, 2023
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Kaveh Matinkhoo, Peter J. Facchini